← brief for 2026-08-13 · Slowing decline
Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists.
Key takeaways
A trial of finerenone in patients with heart failure and kidney disease. The study used 300 patients followed for 2 years.
Who did this work
Khidhir A · Kalra DK
Source
Article · PubMed, the drug frontier · 2026 Aug 13
https://pubmed.ncbi.nlm.nih.gov/42593559/